源于患者 造福患者

人脑的图像,表示患者在驱动科学和医学研究与开发中的意志和脑力。

源于患者 造福患者 TM
发挥患者在推动科学和医学研究与开发中的作用。

映像生物®独特的 源于患者 造福患者TM模式和信念

源于患者 造福患者 TM
     – 凭借坚强的信念,不懈的努力和适合的伙伴,我们作为患者可以积极推动药物研发,达到利己利他的效果。
映像生物 – 源于患者 造福患者®

为什么罕见病患者需要主动推动研发?

迫切未满足的医疗需求

罕见疾病有8,000种。

许多罕见病导致过早死亡或终生残疾。

10%的公众至少患有一种罕见病。

天平的图像,表示罕见疾病患者的紧急医疗需求和悲惨现实之间的不平衡。

可悲的现实

罕见病=较少的商业和研究兴趣。

政府的政策支持虽然大大增加了孤儿药的批准数量。

但是,超过90%的罕见病仍没有任何经过批准的治疗药物。

作为罕见病患者和家人,我们等不起。

The BY PATIENTS, FOR PATIENTS ™ Campaign

 As a patient-driven biotech company, Reflection Biotechnologies (ReflectionBio®) is proud to partner with Invincible Vision, a non-profit patient organization, to jointly launch the BY PATIENTS, FOR PATIENTS ™ awareness and fundraising campaign for Bietti Crystalline Dystrophy  (BCD). BCD is a rare blinding disease with no treatment available.

To support patient-driven research, please make a donation to the BY PATIENTS, FOR PATIENTS ™ campaign. Donations will be used to fund BCD research and advance BCD gene therapy to human clinical trials.

BY PATIENTS, FOR PATIENTS ™ - financial sponsorship

With our BY PATIENTS, FOR PATIENTS ™ approach, ReflectionBio® provides financial sponsorship of scientific, medical, and drug research and development to benefit the rare disease community. For example, ReflectionBio has collaborated with researchers, doctors and contract research organizations (CROs), and initiated and sponsored various R&D projects related to Bietti Crystalline Dystrophy (BCD):

BCD gene therapy preclinical study

BCD gene therapy IND-enabling work

BCD worldwide genetic prevalence study

These R&D projects bring hope to patients suffering from BCD which currently has no treatment available and/or help understand BCD epidemiology.

ReflectionBio®, BY PATIENTS, FOR PATIENTS ™ and ReflectionBio – By Patients, For Patients® are trademarks of Reflection Biotechnologies Limited.

The By Patients, For Patients ™ approach can benefit the rare disease community in many ways

我们作为患者可以通过发起或培育研发项目、发明创新和技术转化等多种方式来推动罕见病的研究和孤儿药物的研发。

发起:

许多罕见疾病缺乏基础研究。
通过发起研发治疗药物的项目,我们,作为患者,可以迈出从0到1的关键一步。

培育:

公共资金对罕见病研究在的支持严重不足。
我们,作为患者,可以整合资源来培育孤儿药物研发。

创新:

罕见病有大约8000种。罕见疾病的信息稀少而且分散。因此对罕见病有深入了解的专家并不多见。
有些罕见疾病患者通过阅读与学习与自身疾病相关的文献,与医生和研究人员的讨论,并结合自身作为患者的经历,积累了大量与自身疾病相关的专业知识。
从基因发现到药物研发,罕见疾病患者可以在推动研发的过程中积极参与,甚至为药物的开发做出贡献。

转化:

最新的科学突破,例如基因疗法,使人们有可能开发出许多针对“无药可治”的罕见病的治疗药物。
我们,作为患者,可以在推动研发方面发挥积极作用,将最新的科学突破转化为临床应用。

我们的进展

以结晶样视网膜色素变性(BCD)为例,以患者为主导的生物技术公司映像生物®,发起并培育了BCD基因疗法的临床前研究,同时在BCD疾病模型和基因疗法候选药物等方面做出了创新 ,并获得了美国食品药物管理局(FDA)的孤儿药资格认证(Orphan Drug Designation),正在将BCD基因疗法推进人体临床试验。

要了解有关映像生物®基于 于患者 造福患者TM 的独特模式在罕见病,孤儿药和基因疗法研究与开发方面取得的进展的更多信息,请参阅研究与开发

双螺旋DNA的图像

BY PATIENTS, FOR PATIENTS TM - what’s more?

Building Rare Disease Knowledge Base

Because rare disease information is scarce, we believe building a rare disease knowledge base is valuable to patients, clinicians and researchers. As a patient-driven biotechnology company, in addition to drug research and development, we spend significant time and efforts on finding, compiling and analysing information on rare diseases for public use.

Promoting Rare Disease Awareness

Furthermore, we work closely with patients, patient organizations and doctors in building rare disease knowledge base and promoting rare disease awareness.

Seeking and Providing Support

Rare disease patients shoulder the inevitable odds of genetic mutations for mankind, but are often ignored by society. Sadly, rare diseases are grossly under-supported by public funding and research resources. As part of our BY PATIENTS, FOR PATIENTS TM approach, Reflection Biotechnologies (ReflectionBio®) also participates in fundraising events and provides financial sponsorship of scientific, medical, and drug research and development, and of projects promoting awareness and knowledge of diseases and healthcare issues and facilitating patients, doctors, and healthcare networks. ReflectionBio® has sponsored projects related to preclinical studies and rare disease epidemiology.

February 23, 2021 (BUSINESS WIRE)–Today, Invincible Vision and ReflectionBio® are launching their inaugural awareness and fundraising campaign, BY PATIENTS, FOR PATIENTS TM, for Bietti’s Crystalline Dystrophy (BCD).

我们的愿景

超越BCD

映像生物在治疗结晶样视网膜色素变性(BCD)的基因疗法研究和开发方面的进步是由我们的创始人兼首席执行官Richard Yang 杨瑞先生推动的。 作为一名罕见病患者,杨瑞在失明过程中启动并推动了BCD基因治疗的临床前研究。 随着更多患者和家人的加入,我们可以做更多的事情,而不仅仅是BCD,我们还可以为更多的视网膜疾病和其他具有挑战性疾病开发治疗药物。